Comparing the current results to its competitors, Vbi Vaccines Inc reported Revenue increase in the 1 quarter 2024 by 150.31 % year on year, while most of its competitors have experienced contraction in revenues by -12.54 %, achieved in the same quarter.
Vbi Vaccines Inc's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes large pharmaceutical firms, specialty pharmaceutical and biotechnology companies, as well as academic and research institutions. The industry is marked by rapid technological advancements, changing standards, emerging competitors, and frequent new product launches. Competitors possess existing products and technologies that rival the company's pipeline candidates and may develop additional competing products. Some competitors have greater financial resources, more extensive service and product offerings, larger research and development investments, enhanced development capabilities, more experience in nonclinical and clinical testing, regulatory approvals, manufacturing, marketing, stronger brand recognition, and better customer access.
August 3, 2024
In a significant development within the biopharmaceutical sector, VBI Vaccines Inc. (NASDAQ: VBIV), known for its immunology-driven breakthroughs, has taken decisive steps to navigate financial headwinds as it implements a strategic restructuring. The company’s challenges and recent decisions underscore the turbulent landscape many biotech firms face in their quest for innovation and sustainability.On July 30, 2024, VBI Vaccines announced its intention to undergo restructuring proceedings, aiming to review its strategic alternatives in the face of evolving market demands. Following the announcement, the company sought legal protection under the Companies Creditors Arrangement Act (CCAA), receiving an initi...
August 2, 2024
CAMBRIDGE, Mass. VBI Vaccines Inc. (Nasdaq: VBIV), a biopharmaceutical company focused on immunology and dedicated to pioneering solutions for the prevention and treatment of diseases, has recently provided important updates on its current restructuring proceedings, as well as significant insights into its ongoing clinical studies and shareholder engagement. Restructuring Proceedings under Chapter 15On July 30, 2024, VBI Vaccines initiated restructuring proceedings aimed at fostering its financial stability and achieving long-term operational goals. The company has since made strides in this regard, with the United States Bankruptcy Court for the District of Delaware granting provisional relief under Chap...
July 30, 2024
VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Facilitate Strategic Alternatives In a significant development for VBI Vaccines Inc. (Nasdaq: VBIV), a leading biopharmaceutical company focused on immunology and the advancement of therapeutic solutions, the Ontario Superior Court of Justice has granted the company protection under the Companies Creditors Arrangement Act (CCAA). This initial order is pivotal as it sets the framework for VBI to explore and implement strategic alternatives that could enhance its operations and financial stability.The restructuring comes at a time when VBI Vaccines continues to reinforce its position as a prominent entity in the immunotherapy landscape, specifical...
May 15, 2024
VBI Vaccines Reports First Quarter 2024 Financial Results and Outlines Key Business StrategiesIn the pursuit of offering robust disease prevention and treatment solutions, VBI Vaccines Inc. has released its financial results for the first quarter of 2024. This article aims to interpret the provided information, outline the facts, and assess their impact on the company s operations.Financial Results and Pipeline Execution:VBI Vaccines has focused on pipeline execution during the first quarter of 2024. While specific details regarding their product pipeline were not mentioned in the given excerpt, it can be inferred that the company has been actively progressing with the development and potential commercializ...
Xbiotech Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic antibodies. They seek to address unmet medical needs by leveraging their proprietary True Human antibody technology.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Opko Health Inc is a biotechnology and pharmaceutical company that operates through various business segments. The company primarily focuses on diagnostics, developing and commercializing novel diagnostic tests for various conditions. Additionally, Opko Health engages in the production and sale of pharmaceuticals and vaccines, as well as the research and development of new medical technologies.
Ocugen Inc's business model is focused on the development and commercialization of innovative gene therapies to treat rare and underserved ocular diseases, with a particular emphasis on underserved patient populations. They aim to leverage their expertise in gene therapy and partnerships to advance novel treatments and bring them to market, ultimately improving the lives of patients in need.
Sources:
Vbi Vaccines Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Vbi Vaccines Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
